Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Max Wang"'
Autor:
Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo
Publikováno v:
Pharmacological Research, Vol 207, Iss , Pp 107340- (2024)
Randomized clinical trials (RCTs) of PCSK9 monoclonal antibody(mAb) specifically for Chinese patients have been limited. This multi-center RCT is to clarify the efficacy and safety of a novel mAb, Ebronucimab, in Chinese patients. Patients diagnosed
Externí odkaz:
https://doaj.org/article/34cb6dc3117e4e9588ec6a9afed8ef2b
Autor:
Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Benchao Chen, Max Wang, Baiyong Li, Michelle Xia, Rodney Sinclair
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2357-2373 (2023)
Abstract Introduction Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subcl
Externí odkaz:
https://doaj.org/article/790d2a45fabb4f539a324f49d5b7130a
Autor:
Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, Max Wang, Michelle Xia, Baiyong Li, Rui Chen, Pei Hu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
AK111 is an innovative IL-17A antibody, presenting high affinity to IL-17A and showing similar pharmacokinetic (PK) characteristics to those of typical immunoglobulin (Ig) G1 antibodies. To optimize the dosage regimen for phase 2/3 clinical trials, P
Externí odkaz:
https://doaj.org/article/b6e6ec5c78d84cef9b441d2c4c5292a2
Autor:
Karamarie Fecho, Stanley C. Ahalt, Michael Knowles, Ashok Krishnamurthy, Margaret Leigh, Kenneth Morton, Emily Pfaff, Max Wang, Hong Yi
Publikováno v:
Frontiers in Artificial Intelligence, Vol 5 (2022)
Research on rare diseases has received increasing attention, in part due to the realized profitability of orphan drugs. Biomedical informatics holds promise in accelerating translational research on rare disease, yet challenges remain, including the
Externí odkaz:
https://doaj.org/article/bf31ac1113cb49b697cfcd537e7313d3
Autor:
Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia, Baiyong Li
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundIgG4 anbibodies are deficient in stability and may contribute to tumor-associated escape from immune surveillance. We developed an IgG1 backbone anti-programmed cell death protein-1 (PD-1) antibody, penpulimab, which is designed to remove c
Externí odkaz:
https://doaj.org/article/ac47a7c60d1f4502a8af848e72115466
Autor:
Yu Xia, Charlotte Lemech, Xiaoping Jin, Jermaine Coward, Anna Mislang, Baiyong Li, Kon Yew Kwek, Yiting Zhou, Max Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/e2bbb355ce1f49c496139fd5c1809379
Autor:
Fang, James Kar-Hei, Tse, Tsz Wan, Maboloc, Elizaldy Acebu, Leung, Ryan Kar-Long, Leung, Matthew Ming-Lok, Wong, Max Wang-Tang, Chui, Apple Pui-Yi, Wang, Youji, Hu, Menghong, Kwan, Kit Yue, Cheung, Siu Gin
Publikováno v:
In Marine Pollution Bulletin February 2023 187
98
The purpose of this research paper is to investigate how a company in a mature industry is capable of remaining competitive by exercising its existing industry resources, and modeling an innovation value chain for itself to highlight the driv
The purpose of this research paper is to investigate how a company in a mature industry is capable of remaining competitive by exercising its existing industry resources, and modeling an innovation value chain for itself to highlight the driv
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/55358326754628296139
Autor:
Shepherd Yuen Chan, Max Wang-Tang Wong, Bonnie Tsz Ching Kwan, James Kar-Hei Fang, Song Lin Chua
Publikováno v:
Environmental Science & Technology Letters. 9:975-982
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.